MONITORING OF ANTIBACTERIAL DRUG SAFETY IN CLINICAL PRACTICE

This paper presents the results of the work of the Regional Centre for Monitoring the Safety of Pharmaceu-ticals in the Irkutsk Region functioning under the aegis of the Federal Service for Surveillance in the Sphere of Circulation of Pharmaceuticals. The analysis is carried out on the basis of the ecological monitoring of adverse reactions to antibacterial drugs. The sample involved 343 cases registered by specialists in the Irkutsk region medical institutions. The gender and age characteristics of the patients experiencing mani-festations of drug toxicity are provided. The clinical manifestations of the complications that developed un-der the influence of chemical antimicrobial factors are systematized. The characteristic symptoms that are predominantly manifested by skin and gastrointestinal tract lesions are described. The groups of antibacte-rial drugs exhibiting the highest risk of complications are identified. The drug monitoring showed that a large number of adverse reactions are associated with two drug classes, i.e., β-lactam antibiotics and fluo-roquinolones (57% cases). The analysis of the effects of cephalosporins and "protected" penicillins re-vealed a high incidence of adverse reactions to ceftriaxone. Key factors reducing the effectiveness of anti-microbial therapy in urinary tract infections are revealed, including a long history of the disease, the pres-ence of two or more urinary tract pathogens, the concomitant infection of upper and lower sections of the urinary tract.

environmental monitoring, treatment, antimicrobial drug safety, security, unwanted adverse reaction

1. Астахова А.В., Лепахин В.К. Лекарства. Неблагоприятные побочные реакции и контроль безопасности. 2-е изд., испр. и доп. М.: Эксмо, 2008. 256 с.

2. Белоусов Ю.Б., Леонова М.В./ Особенности применения лекарства в гериатрической практике // Фарматека. 2008. N 8. С. 13-19.

3. Белоусов Ю.Б., Леонова М.В., Белоусов Д.Ю., и др. Основы клинической фармакологии и рациональной фармакотерапии: рук. для практикующих врачей. М.: Бионика, 2002. 368 с.

4. Верлан Н.В., Рыбалко М.В., Двойникова Н.А., Кочкина Е.О., Гуменникова Е.Н. Проблемы мониторинга безопасного использования лекарственных средств // Сибирский медицинский журнал. 2013. N 6. С. 113-114.

5. Верлан Н.В., Кочкина Е.О., Двойникова Н.А., Рыбалко М.В., Попадюк А.В. Проведение мониторинга безопасности лекарственных средств // Вестник Бурятского государственного университета. Серия: Медицина, фармация. 2014. N 12. С. 13-16.

6. Косенко В.В., Глаголев С.В. Организация системы мониторинга безопасности зарегистрированных лекарственных препаратов в Российской Федерации // Вестник Росздравнадзора. 2012. N 5. С. 25-26.

7. Костылева М.Н., Белоусов Ю.Б., Грацианская А.Н., Постников С.С. Оценка безопасности лекарственной терапии в клинической практике // Фармакоэкономика. 2014. N 1. С. 26-31.

8. Atkin P.A., Shenfield G.M. Medication-related adverse reactions and the elderly: a literature review // Adverse Drug Reactions Toxicol. Rev. 1995. V. 14. P. 175-191.

9. Inmam W.H.W., Rawson N.S.B., Wilton L.V. Monitoring for drug safety. 1985, 213 p.

10. Marshall J.D., Kearns G.L.Developmental pharmacodynamics of cyclosporine. Clin. PharmacolTher. 1999. N 66. P. 66-75.